Centrica Announces Board Succession as Remuneration Chair to Step Down

Centrica ( (GB:CNA) ) has shared an update.

Centrica has announced that Non-Executive Director Carol Arrowsmith, who also chairs the Remuneration Committee, will step down from the board at the conclusion of the company’s 2026 AGM on 7 May, after nearly six years of service. The board has named current director Sue Whalley as the incoming Chair of the Remuneration Committee and a new member of the Nominations Committee, reinforcing continuity in Centrica’s governance and pay oversight structures.

Chair Kevin O’Byrne praised Arrowsmith’s contribution, highlighting her governance expertise and leadership in shaping the company’s remuneration framework over her tenure. The planned transition signals an orderly refresh of Centrica’s board leadership while maintaining focus on rigorous governance in executive pay and nominations, with no additional disclosures required under UK listing rules.

The most recent analyst rating on (GB:CNA) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.

Spark’s Take on GB:CNA Stock

According to Spark, TipRanks’ AI Analyst, GB:CNA is a Neutral.

Centrica’s overall stock score is driven by strong corporate events, particularly the share buyback program and strategic acquisitions, which enhance shareholder value. However, the score is tempered by a challenging valuation due to a negative P/E ratio and mixed technical indicators.

To see Spark’s full report on GB:CNA stock, click here.

More about Centrica

Centrica plc is a UK-based energy company listed on the London Stock Exchange, providing energy supply and related services to residential and business customers. The group operates primarily in the British energy market and is a constituent of major UK equity indices, reflecting its role as a significant player in the utilities sector.

Average Trading Volume: 15,461,609

Technical Sentiment Signal: Buy

Current Market Cap: £8.88B

For a thorough assessment of CNA stock, go to TipRanks’ Stock Analysis page.